In this expert roundtable, three experienced professionals from the rapidly evolving gene therapy field delve into the crucial assessment of AAV potency and its profound influence on the industry's progress.

In this expert roundtable, three experienced professionals from the rapidly evolving gene therapy field delve into the crucial assessment of AAV potency and its profound influence on the industry's progress.

Catalent expert George Buchman, Ph.D., offers insights on key challenges with scaling up production for gene therapies, complexities in the supply chain, regulatory considerations and overall reflections on the industry, progress and future.

Summary: In this article, Catalent expert Victor Vinci discusses what strategies are being employed to accelerate product development and commercialization without compromising quality.

Summary: In this article, Catalent expert Rupa Pike to discusses the manufacturing requirements for a specific cell therapy gaining popularity: CAR T cell therapies.

Summary: In this article, Catalent commented on pricing and approval of advanced therapies.

Summary: In this article, Catalent's George Buchman was asked to respond and give insight into trends across cell and gene therapy and what we can expect to witness this year.

Summary: In this article, Catalent expert, Victor Vinci was asked to respond and give his insight into manufacturing platforms and how they will help drugmakers meet demands.

Summary: In this article, Catalent expert George Buchman discusses the recent increase in gene therapy approvals & how we can accelerate the manufacturing speed with platform processes.

In this episode of “The Top Line”, Fierce Pharma’s Fraiser Kansteiner interviews Delara Motlagh, head of cell therapy at Catalent; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. The conversation covers cell collection, the critical first step in advanced therapy manufacturing.